New clinical trials raise fears that virus is resisting vaccines
South Africa mutation not responding well to shots, may require booster
LOS ANGELES — New data showing that two COVID-19 vaccines are far less effective in South Africa than in other places they were tested have heightened fears that the coronavirus is quickly finding ways to elude the world’s most powerful tools to contain it.
The U.S. company Novavax reported this week that although its vaccine was nearly 90% effective in clinical trials conducted in Britain, the figure fell to 49% in South Africa — and that nearly all the infections the company analyzed in South Africa involved the B.1.351 variant that emerged there late last year and has spread to the U.S. and 30 other countries.
Johnson & Johnson announced Friday that its new shot was 72% effective against preventing moderate or severe illness in the United States, compared with 66% in Latin America and 57% in South Africa.
Laboratory tests had suggested that the vaccines authorized in the U.S. — one from Pfizer and BioNTech, the other from Moderna and the National Institutes of Health — trigger a smaller immune response to the South Africa variant.
Now there is evidence from tests in people that some variants are less vulnerable to certain vaccines.
“From an evolutionary biology perspective, this is totally expected and anticipated,” said Dr. Michael Mina, a Harvard epidemiologist. “But it never feels good to be validated on something so scary.”
Researchers once believed it would take several more months, even years, for the virus to develop vaccine resistance. The speedy evolution is largely due to the virus’ unchecked spread.
More than 100 million people have been infected worldwide, and each of those infections is an opportunity for the virus to randomly mutate.
A mutation that happens to give the virus an advantage, e.g., the ability to resist the body’s natural defenses, can become the basis for a heartier variant. One early sign that this was underway was the significant number of people who were contracting the coronavirus a second time. It appeared that the training their immune systems received during the first infection was failing to protect them from new versions of the virus.
Scientists at Moderna and Pfizer-BioNTech worried the same thing could happen with immunity induced by their vaccines. In laboratories, they took several versions of the virus and exposed them to blood samples from a small number of people who had been vaccinated.
The antibodies produced by Moderna’s vaccine were equally effective against the original coronavirus and the B.1.1.7 strain that emerged in the United Kingdom but were far less effective against the South Africa strain. Pfizer’s vaccine was only slightly less effective against the South Africa variant.Experts had cautioned that laboratory tests were an imperfect model for understanding the immune response in people.
Other parts of the immune system, such as T-cells, might play a role in fighting a variant, even when neutralizing antibodies fall short, said Marc Lipsitch, a Harvard epidemiologist.
That’s why the Novavax trial — the first to test the interactions between variants and vaccines in the real world — was so concerning.
“Whether people who have been vaccinated get infected with the variant — that’s the real proof in the pudding,” said Dr. Otto Yang, an infectious-disease researcher at UCLA.
Novavax cautioned that its South Africa study, which included about 4,400 patients, was too small to offer a precise measurement on the vaccine’s efficacy.
The Johnson & Johnson results provided further evidence that the problem was serious.
Experts said the weaker performance of the vaccine in South Africa — where it was tested on about 6,500 people — almost certainly was a result of the predominance of the variant circulating widely there. Researchers believe that it is more contagious than other variants and that it has become more common in South Africa and elsewhere since the trial began in September.
Researchers said variants were also likely to blame for the subpar showing of the Johnson & Johnson vaccine in Latin America — where it was tested in more than 17,000 people in Argentina, Brazil, Chile, Colombia, Mexico and Peru.
The mutations of greatest concern are on the spike protein on the surface of the virus, because the current crop of vaccines train the immune system to recognize that protein. Mutations there increase the likelihood that the virus will slip by undetected.
Mina, the Harvard epidemiologist, likened the process to searching for a criminal by memorizing the appearance of only his nose and mouth. At first, this may prove sufficient. But if the criminal gets a nose job, investigators will wish they learned about his eyes, ears and hair as well.
Mina said a more diverse arsenal of vaccines, employing a variety of approaches, is needed.
In the meantime, Moderna has announced efforts to develop a booster shot to add to its current two-shot regimen in order to fend off the South Africa variant. The company also plans to test whether a third shot of the original formula could help with other strains.
BioNTech, the company that worked with Pfizer on its shot, is also considering developing an adjusted vaccine.
The United States reported its first known cases of the South Africa variant Thursday, in two people in South Carolina. The U.K. strain, which is also thought to be more contagious, is also circulating here.
In a briefing for reporters Friday, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said the confirmation that more transmissible strains are now in the U.S. is a “wake-up call” that underscores the need to rapidly vaccinate Americans.
“Vaccinating as many people as we can, as quickly as we can” is the key to slowing the ability of the virus to mutate, he said. “Viruses cannot mutate if they cannot replicate.”
The U.S. is vaccinating an average of 1.2 million people a day, said Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention.